Patient Preferences for Noninsulin Diabetes Medications: A Systematic Review

Purnell, Tanjala S.; Joy, Susan; Little, Emily; Bridges, John F. P.; Maruthur, Nisa
July 2014
Diabetes Care;Jul2014, Vol. 37 Issue 7, p2055
Academic Journal
OBJECTIVE An evidence-based synthesis of patient preferences for management of hyperglycemia is needed. Our objective was to systematically review patient preferences for noninsulin diabetes medications in adults with type 2 diabetes. RESEARCH DESIGN AND METHODS We searched the PubMed, Embase, CINAHL, and EconLit databases for articles published on or before 23 January 2013. We included English-language studies of adult patients with type 2 diabetes that assessed patient preferences for diabetes medication treatment. Titles, abstracts, and articles were reviewed by at least two independent reviewers. Study data and quality were abstracted with standard protocols. RESULTS Of 2,811 titles identified in our original search, 10 articles met inclusion criteria for the systematic review. Studies were conducted from 2007 to 2012 among diverse patient populations in the U.S., Sweden, Denmark, and the U.K. Methods used to assess patient preferences included discrete choice experiments (e.g., conjoint analysis), time tradeoff exercises, standard gamble, and patient surveys. Key attributes of diabetes medication associated with patient preferences included treatment benefits (e.g., glycemic control and weight loss/control), treatment burden (e.g., administration, frequency, and cost), and side effects (e.g., weight gain, gastrointestinal effects, and hypoglycemia). CONCLUSIONS Various clinical and quality of life-related factors influence patient preferences for noninsulin diabetes medications. Treatment efficacy with regard to glycemic control and weight loss/control and the risk of treatment-related hypoglycemia and gastrointestinal effects are reported to be important drivers of patient treatment selections. Future work is needed to identify practical methods for incorporating patient preferences into treatment decision making and patient-centered care.


Related Articles

  • Troglitazone for insulin-resistant diabetes.  // American Family Physician;4/1/1997, Vol. 55 Issue 5, p1985 

    Presents information about the approval of the Food and Drug Administration on troglitazone (Rezulin) as the first anti-diabetes drug that targets the underlying cause of type II diabetes mellitus. Required dosage of troglitazone for patients receiving insulin injection; Most common adverse...

  • Improved Postprandial Glycemic Control With Insulin Aspart. Lindholm, Anders; McEwen, John; Riis, Anders P. // Diabetes Care;May99, Vol. 22 Issue 5, p801 

    Presents information on a study which compared the postprandial serum glucose control after administration of insulin aspart, a rapid-acting insulin analog, with that of unmodified human insulin in patients with type one diabetes. Research design and methods; Results; Conclusions.

  • Proceedings of the National Academy of Sciences: Licorice root found to contain anti-diabetic substance.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article focuses on a research, in which researchers have discovered an anti-diabetic substance in the amorfrutin class of natural substances from Licorice root.

  • In This Issue of Diabetes Care. Resnick, Helaine E. // Diabetes Care;Oct2014, Vol. 37 Issue 10, p2663 

    The article discusses various reports published within this issue including one on a study on the effect of albiglutide on diabetic patients, one on the importance of HbA testing to patients with diabetes and one on the effect of fetal hyperglycemia exposure on patients with gestational diabetes...

  • EMD387008, a New Antidiabetic Compound, Inhibits Hepatic Gluconeogenesis through Gluconeogenic Gene Regulation and AMPK Activation. Raynal, Sophie; Audet, Annick; MéSangeau, Didier; Durbin, Philippe; Augert, Guy // Diabetes;Jun2007 Supplement 1, Vol. 56, pA157 

    EMD387008 was previously shown to decrease hyperglycemia of diabetic rats partly by a gluconeogenesis inhibition. This 1st representative of a new class is currently under clinical development for T2DM treatment. The study objective was to investigate in vitro the mechanism of EMD387008-induced...

  • American Diabetes Association - European Association for the study of Diabetes Position statement: Due Dilegence Was conducted. Cefalu, William T. // Diabetes Care;Jun2012, Vol. 35 Issue 6, p1201 

    The article reports on the position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). This effort titled "Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach" is said to be the results from a joint...

  • Evaluation of the Effects of Nateglinide on Postprandial Glycemia in Patients with Type 2 Diabetes mellitus: A Multicenter, Multinational, Non-Randomized, Non-Controlled Latin American Study. Islas-Andrade, Sergio; Revilla-Monsalve, Maria Cristina; Caminos, Quenemari R.; Chacín, Luis F.; Yupanqui, Hernán; López, Gloria; de la Torre, Walter; de Hurtado, Evelyn Martínez // Pharmacology;Jun2003, Vol. 68 Issue 2, p89 

    One hundred and sixteen Latin American type two diabetic patients previously only on a diet were enrolled in this multicenter, multinational, nonrandomized, noncontrolled study. Only 109 completed the study. After eight weeks of treatment with 120 mg of nateglinide, administered prior to each...

  • Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone. LEWIS, JAMES D.; FERRARA, ASSIAMIRA; PENG, TIFFANY; HEDDERSON, MONIQUE; BILKER, WARREN B.; QUESENBERRY JR., CHARLES P.; VAUGHN, DAVID J.; NESSEL, LISA; SELBY, JOSEPH; STROM, BRIAN L. // Diabetes Care;Apr2011, Vol. 34 Issue 4, p916 

    OBJECTIVE--Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy. This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients...

  • Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes. FERRARA, ASSIAMIRA; LEWIS, JAMES D.; QUESENBERRY JR., CHARLES P.; PENG, TIFFANY; STROM, BRIAN L.; VAN DEN EEDEN, STEPHEN K.; EHRLICH, SAMANTHA F.; HABEL, LAUREL M. // Diabetes Care;Apr2011, Vol. 34 Issue 4, p923 

    OBJECTIVE--To explore whether treatment with pioglitazone was associated with risk of incident cancer at the 10 most common sites (prostate, female breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma [NHL], pancreas, kidney/renal pelvis, rectal, and melanoma). RESEARCH DESIGN AND...

  • Repeated Hypoglycemia Caused by the Overproduction of Anti-insulin Antibodies and Isolated ACTH Deficiency in a Type2 Diabetic Patient Receiving Insulin Therapy. YOSHIDA, MASANORI; MURAKAMI, MIHO; OGAWA, KOICHIRO; ASAI, MASATO; MIYATA, MISAKI; MAEDA, HARUMI; OISO, YUTAKA // Diabetes Care;Feb2013, Vol. 36 Issue 2, pe22 

    The article reports on a case of repeated hypoglycemia caused by overproduction of anti-insulin antibodies in a 46-year-old man with untreated type 2 diabetes. One year after his insulin therapy, the patient experienced frequent hypoglycemic attacks which persisted despite reducing his insulin...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics